Current Journal of Neurology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics and Malpractice Statement

AI policies

Indexing and Abstracting

Peer Review Process

Journal Metrics

Podcast

Crocin as a multimodal therapy for multiple sclerosis: Recent breakthroughs in immunomodulation and neuroprotection

Articles in Press

Document Type : Review Article

Authors

1 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Abstract

Background: Multiple sclerosis (MS) is a disabling neurological disorder characterized by the existence of demyelinating lesions and affects more than 2.5 million people globally. The current approaches for patients with MS are mainly based on ameliorating symptoms and decreasing acute attacks, and so far, they have not been successful in providing effective neurological regeneration. Recently, natural-based therapies, like crocin, in light of their pharmacological and biological benefits, have acquired much attention in the treatment of neurological diseases like MS. Hence, this study attempts to answer the question of whether crocin therapy can be a suitable approach for MS with a mechanistic insight.
Methods: In this narrative literature review, all related articles (in press and published) in English were searched and assessed using electronic databases, including Web of Science, PubMed, and Google Scholar, up to April 1, 2025. The search keywords in the title and/or abstract of articles were: "Crocin" or "Crocus Sativus" and "Multiple Sclerosis" or "MS".
Results: Experimental evidence has revealed the ability of crocin to alleviate reflexive motor behavior-related tests, cognitive indices, depressive-like behavior, tail flick latency, the conduction velocity of the motor and sensory nerve, antioxidant factors, and to attenuate inflammatory factors. Besides improving some mental factors, such as anxiety, clinical outcomes indicated that crocin could modulate oxidative stress and inflammation-associated markers.
Conclusion: The current preclinical and clinical studies have provided convincing evidence showing that crocin therapy can be a suitable candidate for MS cases; however, larger and more in-depth clinical trials are warranted to support these results.

Keywords

Main Subjects

References
  1. Garton T, Gadani SP, Gill AJ, Calabresi PA. Neurodegeneration and demyelination in multiple sclerosis. Neuron 2024; 112(19): 3231-51.
  2. Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, Saad HM, Batiha GE, Klionsky DJ. The beneficial role of autophagy in multiple sclerosis: Yes or No? Autophagy 2024; 20(2): 259-74.
  3. Barrie W, Yang Y, Irving-Pease EK, Attfield KE, Scorrano G, Jensen LT, et al. Elevated genetic risk for multiple sclerosis emerged in steppe pastoralist populations. Nature 2024; 625(7994): 321-8.
  4. Liu R, Du S, Zhao L, Jain S, Sahay K, Rizvanov A, et al. Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Front Immunol 2022; 13: 996469.
  5. Maroufi H, Mortazavi SH, Sahraian MA, Eskandarieh S. Environmental risk factors of multiple sclerosis in the Middle East and North Africa region: A systematic review. Curr J Neurol 2021; 20(3): 166-84.
  6. Brown SP. Diagnosis of Cervical Spinal Cord Multiple Sclerosis by a Chiropractic Physician: A Case Report. Cureus 2024; 16(6): e62618.
  7. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med 2020; 133(12): 1380-90.e2.
  8. ArefNezhad R, Motedayyen H, Mohammadi A. Therapeutic Aspects of Mesenchymal Stem Cell-Based Cell Therapy with a Focus on Human Amniotic Epithelial Cells in Multiple Sclerosis: A Mechanistic Review. Int J Stem Cells 2021; 14(3): 241-51.
  9. Mirabella M, Annovazzi P, Brownlee W, Cohen JA, Kleinschnitz C, Wolf C. Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate? Front Neurol 2022; 13: 844873.
  10. Babaesfahani A, Patel P, Bajaj T. Glatiramer. [Updated 2024 Feb 28]. In: StatPearls [Online]. Treasure Island, FL: StatPearls Publishing; 2025. Available from URL: https://www.ncbi.nlm.nih.gov/books/NBK541007/.
  11. Andrade S, Nunes D, Dabur M, Ramalho MJ, Pereira MC, Loureiro JA. Therapeutic Potential of Natural Compounds in Neurodegenerative Diseases: Insights from Clinical Trials. Pharmaceutics 2023; 15(1): 212.
  12. Tancreda G, Ravera S, Panfoli I. Exploring the Therapeutic Potential: Bioactive Molecules and Dietary Interventions in Multiple Sclerosis Management. Curr Issues Mol Biol 2024; 46(6): 5595-613.
  13. Yazdanpanah E, Dadfar S, Shadab A, Orooji N, Nemati M, Pazoki A, et al. Berberine: A natural modulator of immune cells in multiple sclerosis. Immun Inflamm Dis 2024; 12(3): e1213.
  14. Álvarez-Martínez FJ, Díaz-Puertas R, Barrajón-Catalán E, Micol V. Plant-Derived Natural Products for the Treatment of Bacterial Infections. Handb Exp Pharmacol 2025; 287: 265-93.
  15. Ali A, Yu L, Kousar S, Khalid W, Maqbool Z, Aziz A, et al. Crocin: Functional characteristics, extraction, food applications and efficacy against brain related disorders. Front Nutr 2022; 9: 1009807.
  16. Rekabi A, Ram A, Nazari A, Arefnezhad R, Rezaei-Tazangi F. Does crocin create new hope for the treatment of oral problems? A focus on periodontitis. Mol Biol Rep 2024; 51(1): 224.
  17. Veisi A, Akbari G, Mard SA, Badfar G, Zarezade V, Mirshekar MA. Role of crocin in several cancer cell lines: An updated review. Iran J Basic Med Sci 2020; 23(1): 3-12.
  18. Bastani S, Vahedian V, Rashidi M, Mir A, Mirzaei S, Alipourfard I, et al. An evaluation on potential anti-oxidant and anti-inflammatory effects of Crocin. Biomed Pharmacother 2022; 153: 113297.
  19. Naimi H, Khazaei M, Sharifnia F, Hassanian SM, Sayyed-Hosseinian SH. Crocin elicits potent anti-inflammatory and fibrinolytic properties post tendon injury, A new molecule for adhesion therapy. J Tradit Complement Med 2024; 14(6): 687-96.
  20. Azari H, Ebrahimi S, Saeb S, Ghanbari A, Peyravian F, Mokaram P. The Effect of Saffron Aquatic Extract and Crocin on the Differentiation of Neural Stem Cells Into Oligodendrocyte Precursor Cells. Shiraz E-Med J 2018; 19(3): e60190.
  21. Su W, Wang Y, Shao S, Ye X. Crocin ameliorates neuroinflammation and cognitive impairment in mice with Alzheimer's disease by activating PI3K/AKT pathway. Brain Behav 2024; 14(5): e3503.
  22. Tashakori A, Hassanpour S, Vazir B. Protective effect of crocin on cuprizone-induced model of multiple sclerosis in mice. Naunyn Schmiedebergs Arch Pharmacol 2023; 396(8): 1713-25.
  23. Ghiasian M, Khamisabadi F, Kheiripour N, Karami M, Haddadi R, Ghaleiha A, et al. Effects of crocin in reducing DNA damage, inflammation, and oxidative stress in multiple sclerosis patients: A double-blind, randomized, and placebo-controlled trial. J Biochem Mol Toxicol 2019; 33(12): e22410.
  24. Shah A, Panchal V, Patel K, Alimohamed Z, Kaka N, Sethi Y, et al. Pathogenesis and management of multiple sclerosis revisited. Dis Mon 2023; 69(9): 101497.
  25. Lopez JA, Denkova M, Ramanathan S, Dale RC, Brilot F. Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. Clin Transl Immunology 2021; 10(7): e1316.
  26. Amoriello R, Memo C, Ballerini L, Ballerini C. The brain cytokine orchestra in multiple sclerosis: from neuroinflammation to synaptopathology. Mol Brain 2024; 17(1): 4.
  27. Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 2019; 142(7): 1858-75.
  28. Lassmann H. Multiple Sclerosis Pathology. Cold Spring Harb Perspect Med 2018; 8(3): a028936.
  29. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707-17.
  30. Jafarzadeh Bejargafshe M, Hedayati M, Zahabiasli S, Tahmasbpour E, Rahmanzadeh S, Nejad-Moghaddam A. Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis. Stem Cell Investig 2019; 6: 44.
  31. Yousefi F, Lavi Arab F, Saeidi K, Amiri H, Mahmoudi M. Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: Focus on mesenchymal stem cells and neuroprotection. J Neuroimmunol 2019; 328: 20-34.
  32. Rahmati M, Ghannadian SM, Kasiri N, Ahmadi L, Motedayyen H, Shaygannejad V, et al. Modulation of Th17 Proliferation and IL-17A Gene Expression by Acetylated Form of Apigenin in Patients with Multiple Sclerosis. Immunol Invest 2021; 50(2-3): 216-29.
  33. Sedaghat N, Motedayyen H, Alsahebfosoul F, Etemadifar M, Ostadi V, Kianpour F, et al. Increased Expression of Lymphocyte Activation Gene-3 by Regulatory T Cells in Multiple Sclerosis Patients with Fingolimod Treatment. Turk J Immunol 2019; 7(1): 31.
  34. Motedayyen H, Rezaei A, Zarnani AH, Tajik N. Human amniotic epithelial cells inhibit activation and pro-inflammatory cytokines production of naive CD4+ T cells from women with unexplained recurrent spontaneous abortion. Reprod Biol 2018; 18(2): 182-8.
  35. McLaughlin KA, Wucherpfennig KW. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 2008; 98: 121-49.
  36. Rissanen E, Tuisku J, Vahlberg T, Sucksdorff M, Paavilainen T, Parkkola R, et al. Microglial activation, white matter tract damage, and disability in MS. Neurol Neuroimmunol Neuroinflamm 2018; 5(3): e443.
  37. Datta G, Colasanti A, Rabiner EA, Gunn RN, Malik O, Ciccarelli O, et al. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain 2017; 140(11): 2927-38.
  38. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8(11): 647-56.
  39. Fatemi R, Moghaddam HF, Farbod Y, Beygtashkhani R. Effects of Crocin on brain neurotrophins, cognition, balance and pain in toxic-induced demyelination model. Acta Neurol Taiwan 2024; 33(2): 48-59.
  40. Hua LH, Hersh CM, Morten P, Kusel J, Lin F, Cave J, et al. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis. J Manag Care Spec Pharm 2019; 25(4): 490-8.
  41. Hooshyari Ardakani M, Nosengo C, Felletti S, Catani M, Cavazzini A, De Luca C, et al. Enhancing the purification of crocin-I from saffron through the combination of multicolumn countercurrent chromatography and green solvents. Anal Bioanal Chem 2024; 416(10): 2553-64.
  42. Pazoki A, Askaripour M, Zargarani S, Yazdanpanah E, Haghmorad D. Crocin as a potential therapeutic agent for multiple sclerosis: insights from experimental autoimmune encephalomyelitis model in mice. Immunopharmacol Immunotoxicol 2025; 47(1): 131-9.
  43. Sonar SA, Lal G. Differentiation and Transmigration of CD4 T Cells in Neuroinflammation and Autoimmunity. Front Immunol 2017; 8: 1695.
  44. Pawlak M, Ho AW, Kuchroo VK. Cytokines and transcription factors in the differentiation of CD4(+) T helper cell subsets and induction of tissue inflammation and autoimmunity. Curr Opin Immunol 2020; 67: 57-67.
  45. Mirzaei R, Zamani F, Hajibaba M, Rasouli-Saravani A, Noroozbeygi M, Gorgani M, et al. The pathogenic, therapeutic and diagnostic role of exosomal microRNA in the autoimmune diseases. J Neuroimmunol 2021; 358: 577640.
  46. Ahmadi SA, Kazemi A, Sabahi M, Razipour S, Salehipour A, Ghiasian M, et al. Probable antioxidant therapy of Saffron Crocin in patients with multiple sclerosis: A randomized controlled trial. Biomedicine 2020; 40(4): 516-21.
  47. Kouchaki E, Rafiei H, Ghaderi A, Azadchehr MJ, Safa F, Omidian K, et al. Effects of crocin on inflammatory biomarkers and mental health status in patients with multiple sclerosis: A randomized, double-blinded clinical trial. Mult Scler Relat Disord 2024; 83: 105454.
  48. Rezaeimanesh N, Rafiee P, Saeedi R, Khosravian P, Sahraian MA, Eskandarieh S, et al. The effect of crocin-selenium nanoparticles on the cognition and oxidative stress markers of multiple sclerosis patients: a randomized triple-blinded placebo-controlled clinical trial. Biometals 2024; 37(2): 305-19.
  49. Foo EC, Russell M, Lily O, Ford HL. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone. Mult Scler Relat Disord 2020; 44: 102330.
  50. Nonino F, Baldin E, Ridley B, Casetta I, Iuliano G, Filippini G. Azathioprine for people with multiple sclerosis. Cochrane Database Syst Rev 2021; 2021(7): CD015005.
  51. Bathaei P, Imenshahidi M, Vahdati-Mashhadian N, Hosseinzadeh H. Effects of Crocus sativus and its active constituents on cytochrome P450: a review. Naunyn Schmiedebergs Arch Pharmacol 2025; 398(9): 11407-20.
  52. Moratalla-López N, Bagur MJ, Lorenzo C, Salinas M, Alonso GL. Bioactivity and Bioavailability of the Major Metabolites of Crocus sativus L. Flower. Molecules 2019; 24(15): 2827.
Current Journal of Neurology

Articles in Press, Accepted Manuscript
Available Online from 05 January 2026
Files
Share
How to cite
Statistics